Langerhans cell histiocytosis · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cladribine and Cytarabine Variant #01 | — | R 84 432 | 21d | — | — | — | — | — |
Cladribine monotherapy Variant #01 | — | R 59 905 | 5d | — | — | — | — | — |
Cobimetinib monotherapy Variant #01 | — | R 28 004 | 28d | — | — | — | — | — |
Vemurafenib monotherapy Variant #01 | — | R 13 464 | 28d | ~7.2 mo | ~15.5 mo | ~8 | ~R 107 711 PFS proxy · indirect | 4 |
4 of 4 regimens shown